Discover
ACET
Adicet Bio, Inc.
3.42
2 x 3.74
1 x 3.80
bid
ask
-
0.16
4.47%
2 @ 04:00 PM
3.42 +0.00 (0.00%)
| Ytd | -59.38% | |
| 1y | -72.55% |
3.33
day range
3.74
3.33
52 week range
12.94
| Open | 3.74 | Prev Close | 3.58 | Low | 3.33 | High | 3.74 | Mkt Cap | 32.02M |
| Vol | 242.49K | Avg Vol | 196.92K | EPS | -10.42 | P/E | N/A | Forward P/E | -0.69 |
| Beta | 1.70 | Short Ratio | 7.04 | Inst. Own | 76.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 7.26 | 200-d Avg | 7.72 | 1yr Est | 6.40 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-19 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-11-18 | HC Wainwright & Co. | Upgrade | Neutral | |
| 2024-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-14 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2024-07-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-04 | CHODAKEWITZ JEFFREY | Director | 11.80K | Stock Award(Grant) |
| 2024-06-04 | DUBIN STEVE | Director | 16.80K | Stock Award(Grant) |
| 2024-06-04 | GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | 11.46M | Stock Award(Grant) |
| 2024-01-23 | HARVEY BRIAN NICHOLAS | Chief Financial Officer | 99.80K | Stock Award(Grant) |
| 2024-06-04 | JAKOBOVITS AYA | Director | 862.56K | Stock Award(Grant) |
| 2024-06-04 | KAUFFMAN MICHAEL G | Director | 5.90K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Orbimed Advisors LLC. | 11.45M | 10.49M | 13.89% |
| 2024-09-29 | Tang Capital Management, LLC | 8.22M | 7.53M | 9.97% |
| 2024-09-29 | RA Capital Management, L.P. | 7.54M | 6.91M | 9.15% |
| 2024-09-29 | Goldman Sachs Group Inc | 3.76M | 3.44M | 4.56% |
| 2024-09-29 | Vanguard Group Inc | 3.21M | 2.94M | 3.89% |
| 2024-09-29 | Carlyle Group Inc. | 2.95M | 2.70M | 3.58% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.07M | 1.90M | 2.51% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.08M | 989.04K | 1.31% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Fund | 660.30K | 604.97K | 0.80% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 351.42K | 321.97K | 0.43% |
| 2024-10-30 | Fidelity Enhanced Small Cap ETF | 222.49K | 203.84K | 0.27% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 191.30K | 175.27K | 0.23% |
Dividend
| Dividend | Date |
|---|---|
| 0.0001 | 2018-09-21 |
| 0.0001 | 2018-06-07 |
| 0.0006 | 2018-03-08 |
| 0.0006 | 2017-12-15 |
| 0.0006 | 2017-09-07 |
| 0.0006 | 2017-06-07 |
Split
| Split | Date |
|---|---|
| 1 : 16 | 2025-12-30 |
| 1 : 7 | 2020-09-16 |
| 1.5 : 1 | 2005-01-11 |
| 1.5 : 1 | 2004-01-05 |
| 1.5 : 1 | 2003-01-03 |
| 1.5 : 1 | 1998-04-14 |